MedPath

Calcitriol

Generic Name
Calcitriol
Brand Names
Rocaltrol, Vectical
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
32222-06-3
Unique Ingredient Identifier
FXC9231JVH
Background

Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to Vitamin D3 (vitamin D3) in the skin, which is then converted to Calcifediol in the liver and kidneys. Calcifediol undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity . Calcitriol is considered to be the most potent metabolite of vitamin D in humans . Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate . Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal tubular reabsorption of calcium in the kidneys, and stimulating the release of calcium stores from the skeletal system. In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways of classical nuclear receptors (nVDR), where calcitriol acts as a natural ligand . There is also evidence that calcitriol modulates the action of cytokines and may regulate immune and inflammatory response, cell turnover, cell differentiation .

Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of secondary hyperparathyroidism and resultant metabolic bone disease, hypocalcemia in patients undergoing chronic renal dialysis, and osteoporosis. It is also available in topical form for the treatment of mild to moderate plaque psoriasis in adults. Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis).

Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Associated Conditions
Hypocalcemia, Mild to Moderate Plaque Psoriasis, Osteodystrophy, Secondary Hyperparathyroidism (SHPT), Vitamin D Resistant Rickets

Bone Mass and Strength After Kidney Transplantation

Phase 2
Completed
Conditions
End Stage Renal Disease
Fractures
Kidney Transplantation
Bone Loss
Vascular Calcifications
Interventions
First Posted Date
2014-08-25
Last Posted Date
2025-03-07
Lead Sponsor
Columbia University
Target Recruit Count
61
Registration Number
NCT02224144
Locations
🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

Plaque Psoriasis Study in Pediatric Subjects

Phase 4
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: placebo comparator
First Posted Date
2014-07-10
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
19
Registration Number
NCT02186665
Locations
🇧🇪

UCL Saint Luc, Brussel, Belgium

🇩🇪

University of Tübingen, Tubingen, Germany

🇺🇸

Dermatology and Laser Center of Charleston, Charleston, South Carolina, United States

and more 31 locations

Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Phase 4
Completed
Conditions
Psoriasis Vulgaris
Interventions
First Posted Date
2014-04-29
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
54
Registration Number
NCT02125279
Locations
🇺🇸

Johnson Dermatology, Fort Smith, Arkansas, United States

🇺🇸

Advanced Skincare Surgery & Medcenter, Burbank, California, United States

🇺🇸

University of South Florida, Tampa, Florida, United States

and more 13 locations

RA-2 13-cis Retinoic Acid (Isotretinoin)

Phase 2
Completed
Conditions
Male Infertility
Klinefelter's Syndrome
Y-chromosome Microdeletions
Interventions
Drug: 13-cis retinoic acid
First Posted Date
2014-02-12
Last Posted Date
2021-08-02
Lead Sponsor
University of Washington
Target Recruit Count
20
Registration Number
NCT02061384
Locations
🇺🇸

University of Washington Medical Center, Seattle, Washington, United States

Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease

Early Phase 1
Completed
Conditions
Anemia of Chronic Disease
Chronic Kidney Disease
Interventions
First Posted Date
2013-11-20
Last Posted Date
2015-08-24
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
40
Registration Number
NCT01988116
Locations
🇺🇸

University of Alabama, Birmingham, Alabama, United States

Safety Study of an Oral Vitamin D Analog in Postmenopausal Women

Phase 1
Completed
Conditions
Postmenopausal Osteoporosis, Multiple Sites
Interventions
First Posted Date
2013-10-25
Last Posted Date
2017-07-27
Lead Sponsor
Deltanoid Pharmaceuticals
Registration Number
NCT01969656

The Effect of Calcitriol on Progress and Activity of Lupus Nephritis

Phase 2
Conditions
Systemic Lupus Erythematosus
Interventions
Drug: placebo
First Posted Date
2013-05-29
Last Posted Date
2013-05-29
Lead Sponsor
Guilan University of Medical Sciences
Target Recruit Count
50
Registration Number
NCT01863641
Locations
🇮🇷

Razi hospital, Rasht, Guilan, Iran, Islamic Republic of

Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD

Phase 4
Conditions
Chronic Kidney Disease
Proteinuria
Interventions
First Posted Date
2013-03-29
Last Posted Date
2013-03-29
Lead Sponsor
Huashan Hospital
Target Recruit Count
60
Registration Number
NCT01820832
Locations
🇨🇳

Huashan Hospital, Fudan University, Shanghai, Shanghai, China

Paricalcitol Effect on Anemia in CKD

Phase 4
Completed
Conditions
Anemia
Chronic Kidney Disease
Interventions
First Posted Date
2013-01-15
Last Posted Date
2014-07-30
Lead Sponsor
Federico II University
Target Recruit Count
60
Registration Number
NCT01768351
Locations
🇮🇹

Federico II University, Naples, Italy

PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis

Phase 4
Completed
Conditions
Plaque Psoriasis
Interventions
First Posted Date
2013-01-11
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
18
Registration Number
NCT01766440
Locations
🇺🇸

Menter Dermatology Research Institute, Dallas, Texas, United States

🇺🇸

Seattle Children's Hospital, Seattle, Washington, United States

🇺🇸

Rady Children's Hospital - Pediatric and Adolescent Dermatology, San Diego, California, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath